Connect with us

BIOTECH

InMed Pharmaceuticals, Inc. (OTCMKTS:IMLFF) Updates Pain Program

Published

on

InMed Pharmaceuticals, Inc. (OTCMKTS:IMLFF) reported additional pre-clinical data in the advancement of INM-405 for the cure of pain. In recent pre-clinical assessment, the company employed numerous methods to substantiate the effects of individual, non-THC cannabinoids, and a matrix of cannabinoid combinations, offered to cure peripheral pain.

These methods include in vivo animal models of pain to estimate the pain tolerance; in vivo behavioral trials to verify the CNS related side effects; and in vivo electrophysiology recordings to know the blockage of pain signal spread in the peripheral nerve fibres.

The highlights

Results from the recent data indicate that peripheral application of specific cannabinoid compounds, in combination or alone, is effective in the cure of craniofacial muscle pain disorders, with no CNS side effects noted, and may be a more desirable plan as compared to systemic pain-relief administration.

Previously, InMed announced the expression of both CB2 and CB1 receptors in trigeminal ganglion neurons stimulating the masseter muscle, offering indication that these receptors can be marks for craniofacial muscle pain. CB2 and CB1 receptors are main targets in the body for cannabinoid medications.

There is a requirement to find options to treat severe and chronic pain that have limited side effects and are non-addictive. InMed continues to work upon the potential of non-THC CBDs to treat pain utilizing a topical formulation. The company’s proof of concept trial data published in the European Journal of Pain this July, showcased the topical use of THC to successfully cure peripheral pain.

Recently, the company submitted a provisional patent application in the U.S. for INM-405 and other innovative compositions as CBD-based topical therapies for the cure of pain, which is a vital step in safeguarding InMed’s commercial and intellectual property. The base of this patent is the unreported results, mentioned above, on non-THC CBDs and their ability to regulate pain. The patent mentions a range of CBDs, alone or in combination, smeared topically to treat several types of pain – nerve, arthritis-induced joint pain, muscle, etc.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement
Advertisement

Symbol        Alert        High        Gain

 

  VBIO          $0.67       $4.10      500%

  IMLFF        $0.11       $0.57      400%

  CMXC        $0.25       $0.45      80%

  REPCF       $0.54       $0.79      48%

 

Get Your Latest Winner Delivered to Your Inbox!

FREE

For The Next 48 Hours

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement